Brexit: UK Industry Body Slams 'Ill Considered' Guidance On Batch Testing
Time Limit Placed On Acceptance Of Overseas Test Results
The UK BioIndustry Association says the updated guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
You may also be interested in...
Having to set up duplicate testing facilities in the EU and the UK is an expensive business, so pharmaceutical companies are relieved that the UK is giving them some extra breathing space.
The post-Brexit agreement between the UK and the EU leaves some grey areas in the field of medicines regulation. The UK government is coming under pressure to clarify the situation.
Hope is not lost as the EU sees a "narrow path" to a trade deal with the UK, but the life sciences industry is still facing uncertainty over key issues such as medicines batch testing.